<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40186635</article-id><article-id pub-id-type="pmc">PMC11972184</article-id>
<article-id pub-id-type="publisher-id">13068</article-id><article-id pub-id-type="doi">10.1007/s00415-025-13068-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Communication</subject></subj-group></article-categories><title-group><article-title>Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hong</surname><given-names>J&#x000e9;r&#x000e9;my</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gaubert</surname><given-names>Malo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lefort</surname><given-names>Mathilde</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferr&#x000e9;</surname><given-names>Jean Christophe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Le Page</surname><given-names>Emmanuelle</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Michel</surname><given-names>Laure</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Labauge</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pelletier</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>de Seze</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Durand-Dubief</surname><given-names>Fran&#x000e7;oise</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Cotton</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Edan</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bannier</surname><given-names>Elise</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Comb&#x000e8;s</surname><given-names>Benoit</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4530-3553</contrib-id><name><surname>Kerbrat</surname><given-names>Anne</given-names></name><address><email>anne.kerbrat@chu-rennes.fr</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qec5a53</institution-id><institution-id institution-id-type="GRID">grid.411154.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 0984</institution-id><institution>Univ Rennes, CHU Rennes, Service de radiologie, </institution></institution-wrap>35000 Rennes, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/015m7wh34</institution-id><institution-id institution-id-type="GRID">grid.410368.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2191 9284</institution-id><institution>EMPENN research team, U1128, Univ Rennes, Inria, CNRS, Inserm, IRISA UMR 6074, </institution></institution-wrap>Rennes, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/015m7wh34</institution-id><institution-id institution-id-type="GRID">grid.410368.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2191 9284</institution-id><institution>Univ Rennes, EHESP, CNRS, Inserm, Ar&#x000e8;nes - UMR 6051, RSMS (Recherche sur les Services et Management en Sant&#x000e9;) - U 1309, </institution></institution-wrap>35000 Rennes, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/015m7wh34</institution-id><institution-id institution-id-type="GRID">grid.410368.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2191 9284</institution-id><institution>Univ Rennes, CHU Rennes, Service de Neurologie, CHU Pontchaillou, </institution></institution-wrap>2 RUE Henri Le Guilloux, 35000 Rennes, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mthsf17</institution-id><institution-id institution-id-type="GRID">grid.157868.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9961 060X</institution-id><institution>Neurology department, </institution><institution>Montpellier University Hospital, </institution></institution-wrap>Montpellier, France </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035xkbk20</institution-id><institution-id institution-id-type="GRID">grid.5399.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2176 4817</institution-id><institution>Aix Marseille Univ, APHM, P&#x000f4;le de Neurosciences Cliniques, MICeME, </institution></institution-wrap>Marseille, France </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035xkbk20</institution-id><institution-id institution-id-type="GRID">grid.5399.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2176 4817</institution-id><institution>Aix Marseille Univ, CNRS, CRMBM, </institution></institution-wrap>Marseille, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bckew43</institution-id><institution-id institution-id-type="GRID">grid.412220.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2177 138X</institution-id><institution>CIC Strasbourg INSERM 1434, </institution><institution>Strasbourg University Hospital, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01502ca60</institution-id><institution-id institution-id-type="GRID">grid.413852.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 3825</institution-id><institution>Neurology Department, </institution><institution>Lyon University Hospital, </institution></institution-wrap>Lyon, France </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01502ca60</institution-id><institution-id institution-id-type="GRID">grid.413852.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 3825</institution-id><institution>Department of Radiology, UMR 5220 &#x00026; INSERM U1044, </institution><institution>Lyon Sud Hospital, Hospices Civils de Lyon, France CREATIS - CNRS, University Claude Bernard Lyon 1, </institution></institution-wrap>Lyon, France </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>272</volume><issue>4</issue><elocation-id>316</elocation-id><history><date date-type="received"><day>8</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The utility of systematic spinal cord (SC) MRI for monitoring disease activity after a multiple sclerosis (MS) diagnosis remains a topic of debate.</p></sec><sec><title>Objectives</title><p id="Par2">To evaluate the frequency of disease activity when considering brain MRI alone versus both brain and SC MRI and to identify factors associated with the occurrence of new SC lesions.</p></sec><sec><title>Methods</title><p id="Par3">We conducted a retrospective analysis of clinical and imaging data prospectively collected over 5&#x000a0;years as part of the EMISEP cohort study. A total of 221 intervals (with both brain and spinal cord MRI scans available at 2 consecutive time-points) from 68 patients were analysed. For each interval, brain (3D Fluid-Attenuated Inversion Recovery (FLAIR, axial T2 and axial PD) and SC MRI (sagittal T2 and phase-sensitive inversion recovery, axial T2*w and 3D T1) were reviewed to detect new lesions. Each interval was classified as symptomatic (with relapse) or asymptomatic. The baseline brain and SC lesion numbers were computed.</p></sec><sec><title>Results</title><p id="Par4">SC MRI activity without clinical relapse and/or brain MRI activity was rare (4 out of 221 intervals, 2%). The occurrence of a new SC lesion was associated with the number of brain lesions at baseline (OR =&#x02009;1.002 [1.000; 1.0004],<italic> p</italic>&#x02009;= 0.015) and the occurrence of a new brain lesion during the interval (OR =&#x02009;1.170 [1.041; 1.314], <italic>p</italic>&#x02009;= 0.009), but not with the baseline SC lesion number (<italic>p</italic>&#x02009;= 0.6).</p></sec><sec><title>Conclusion</title><p id="Par5">These findings support the current guidelines recommending routine disease monitoring with brain MRI alone, even in patients with a high SC lesion load.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00415-025-13068-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Spinal cord</kwd><kwd>MRI</kwd><kwd>Multiple sclerosis</kwd><kwd>Disease activity</kwd><kwd>Longitudinal study</kwd></kwd-group><funding-group><award-group><funding-source><institution>PHRC</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Centre Hospitalier Universitaire de Rennes</institution></funding-source></award-group><open-access><p>Open access funding provided by Centre Hospitalier Universitaire de Rennes.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Spinal cord (SC) lesions are common in people with MS (pwMS), occurring in approximately 80% of the cases [<xref ref-type="bibr" rid="CR1">1</xref>]. They are included in diagnosis criteria [<xref ref-type="bibr" rid="CR2">2</xref>] and have a strong prognosis value early in the disease course [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, the role of SC MRI in monitoring disease activity and treatment response after diagnosis is still debated. This is mainly due to challenges in interpreting longitudinal SC MRI images, time (doubling), and therefore costs, and the idea that SC lesions are unlikely to be asymptomatic. Accordingly, SC MRI is currently not recommended routinely in the international guidelines, with the exception of specific clinical situations [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">Nevertheless, prior studies [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>] have reported that asymptomatic SC lesions occur in 15&#x02013;30% of clinically stable pwMS and approximately 10% had asymptomatic SC lesions without asymptomatic brain lesions, implying that a proportion of patients with disease activity may be missed with brain MRI only. In contrast, another recent large study limited to cervical spinal cord had reported only 1.9% of pwMS with new isolated asymptomatic SC lesions during follow-up [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">In addition to these conflicting results, several limitations can be identified. First, most of these studies were retrospective with SC MRI rarely performed routinely, potentially leading to an over-representation of patients with SC symptoms. Moreover, SC imaging protocols likely influenced detection rates. For example, axial sequences greatly increase the detection rate of SC lesions compared with sagittal sequences alone [<xref ref-type="bibr" rid="CR11">11</xref>], and sequences such as phase-sensitive inversion recovery (PSIR) [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] have demonstrated a better detection rate, with better confidence of cervical SC MS lesions compared to sagittal T2 and short TI inversion recovery (STIR) sequences.</p><p id="Par9">Taking into account these limitations, the present study focussed on a cohort of relapsing remitting MS (RRMS) patients in the first years after diagnosis, with prospective follow-up including systematic both brain and spinal cord MRI over a period of 5&#x000a0;years. Multisequence SC acquisitions were performed to optimise new SC lesions detection and a systematic reading of brain MRI using artificial intelligence (AI)-based tools as an aid to radiological reading was conducted [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Our primary objective was to describe the number of intervals regarded as active when both brain and SC MRIs were considered versus when only brain MRI was analysed. We also investigated the factors associated with the occurrence of new brain or SC lesions to identify subpopulations of pwMS who might benefit from routine SC MRI monitoring. Finally, the prognostic value of presenting a new SC lesion compared to new brain lesion only on subsequent relapse and disability worsening was evaluated.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Participants</title><p id="Par10">We conducted a retrospective analysis of clinical and imaging data that were prospectively collected in the EMISEP multicentre research cohort (EMISEP, ClinicalTrials ID: NCT02117375 [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]). The study was approved by the institutional review board and written informed consents were obtained from all participants. The main inclusion criteria in the EMISEP cohort were: relapsing&#x02013;remitting multiple sclerosis (RRMS) diagnosis according to the 2010 criteria [<xref ref-type="bibr" rid="CR19">19</xref>]; age between 18 and 45 years old; first relapse within 12 months prior the inclusion; initial MRI severity &#x0003e;&#x02009;9 T2 brain lesions and/or initial myelitis documented on SC MRI; Expanded Disability Status Scale (EDSS) &#x02264;&#x02009;3; no relapse and no corticosteroids within the month before inclusion. The patients were enrolled between 2014 and 2017, and underwent clinical and radiological assessments at baseline, 12, 24, 36 and 60 months. For the present study, we included patients from the initial EMISEP cohort with at least both brain and spinal cord MRI scans of sufficient quality (i.e. without significant artefacts compromising interpretation) available at 2 time-points during follow-up. Thus, of the 81 patients enrolled in the initial EMISEP cohort, 68 were included in the present study (centres: Marseille =&#x02009;5, Montpelier =&#x02009;11, Rennes =&#x02009;44, Strasbourg =&#x02009;6 and Toulouse =&#x02009;2) with 221 intervals analysed (i.e. with both brain and spinal cord MRI scans available at two consecutive time-points. For each patient, MRI scans were paired with no repetition of the same initial time-point when more than two time-points were available).</p></sec><sec id="Sec4"><title>Clinical assessment and definitions</title><p id="Par11">Neurologists specialising in MS conducted clinical evaluations every six months, recording relapse occurrence, disease-modifying therapy (DMT) use, and EDSS scores. A relapse was defined as the development of new or reactivation of pre-existing neurological symptoms lasting a minimum of 24 h in the absence of fever or infection, occurring at least 30 days after the preceding relapse. The relapses were confirmed by a supplementary visit with a clinical assessment performed by a MS specialist in the EMISEP study. An interval between two MRI scans during follow-up was considered as symptomatic if a relapse has occurred during this interval, and asymptomatic otherwise. The therapeutic strategy during each interval, and for each patient was defined as &#x0201c;under high efficacy therapy&#x0201d; (HET), &#x0201c;under medium efficacy therapy&#x0201d; (MET), &#x0201c;untreated&#x0201d;, or &#x0201c;switch between therapeutic strategies&#x0201d;. An interval &#x0201c;under HET&#x0201d; was defined as an interval under natalizumab, mitoxantrone, alemtuzumab or antiCD20 (between 3&#x000a0;months after treatment start and until treatment stop for natalizumab, and between 3&#x000a0;months after treatment start and until 1&#x000a0;year after treatment stop for the other HET). An interval &#x0201c;under MET&#x0201d; was defined as an interval under interferon, glatiramer acetate, teriflunomide, dimethyl Fumarate or fingolimod (between 6&#x000a0;months after treatment start and until treatment stop). An &#x0201c;untreated&#x0201d; interval was defined as an interval without any DMT. A &#x0201c;switch&#x0201d; interval corresponded to all the other periods. A disability worsening was defined as a confirmed and maintained until the last follow-up EDSS increase of 1.5 points for patients with baseline EDSS =&#x02009;0, 1 point from 1 to 5.5, and 0.5 points for &#x0003e;&#x02009;5.5.</p></sec><sec id="Sec5"><title>MRI assessment</title><p id="Par12">MRI scans were performed using 3&#x000a0;T MRI scanners from the same manufacturer (Rennes, Strasbourg, Marseille: MAGNETOM Verio (VB17); Montpellier, Toulouse: MAGNETOM Skyra (VD13); Siemens Healthineers, Erlangen, Germany). Details of acquisition parameters are given in the Supplemental Material. Briefly, the same MR sequences and parameters were used across the centres: 1) for SC: sagittal T2-weighted TSE (T2w) and sagittal phase-sensitive inversion recovery (PSIR), with separate acquisitions for cervical and thoracic SC, and axial T2*-weighted (T2*w) and 3D T1-weighted (T1w) sequences from C1 to C7; 2) for the brain: axial T2-weighted, axial proton density (PD), and 3D fluid-attenuated inversion recovery (FLAIR).</p></sec><sec id="Sec6"><title>Image analysis</title><sec id="Sec7"><title>Baseline image analysis</title><p id="Par13">A cross-sectional lesion segmentation was performed using deep-learning based automatic tools [<xref ref-type="bibr" rid="CR20">20</xref>] for both brain (on 3D FLAIR) and spinal cord (on sagittal T2) acquisitions at baseline for each patient. SC lesion masks were systematically reviewed by JH, a radiology resident and manually adjusted if necessary.</p></sec><sec id="Sec8"><title>Longitudinal image analysis</title><p id="Par14">The 221 pairs of brain and spinal cord MRI scans were systematically reviewed by JH, blinded from the initial radiological reports performed by a neuroradiologist and from clinical information. For brain images, all available acquisitions (3D FLAIR, axial T2, and axial PD) were used to identify new/enlarging lesions, with the systematic help of a deep-learning-based tool (not used in initial reading) supplemented by registered 3D FLAIR volumes. The details regarding the deep-learning based tool use are available in [<xref ref-type="bibr" rid="CR16">16</xref>]. The definition of &#x0201c;enlarging lesions&#x0201d; was left to the discretion of the radiologist, as is done in routine clinical practice, and in the absence of a precise definition in the current guidelines [<xref ref-type="bibr" rid="CR5">5</xref>]. New/enlarging brain lesions were then reviewed and manually corrected, if necessary, by JH on the 3D FLAIR volume using ITK-SNAP software (version 4.0.1, [<xref ref-type="bibr" rid="CR21">21</xref>]). For SC images, sagittal T2, PSIR, axial T2* and 3D T1 were used to identify new/enlarging lesions supplemented by registered sagittal T2 volumes. New/enlarging SC lesions were segmented on the sagittal T2 images, distinguishing the two acquisitions: &#x0201c;upper&#x0201d; and &#x0201c;lower&#x0201d;. These acquisitions (upper/lower) were an approximation of cervical and thoracic SC (the &#x0201c;upper&#x0201d; acquisition usually including a few thoracic vertebrae). In a second time, patient classification (as active (i.e. with new/enlarging T2 lesion) or inactive on brain and spinal cord MRI) was compared to the initial classification based on the initial radiological report. In case of discrepancies, images were reviewed by JH and another reader (AK, neurologist with 10 years of experience in interpreting brain and spinal cord MRI in pwMS) to correctly classify the patient (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Number and volume of cross-sectional lesions and new lesions between two time-points were extracted using FSL software (version 6.0.5, [<xref ref-type="bibr" rid="CR22">22</xref>]) (fslstats and cluster).<fig id="Fig1"><label>Fig. 1</label><caption><p>Examples of brain and spinal cord lesions segmentation at baseline and follow up (M12) in the same patient. <bold>a</bold> Baseline brain lesions segmentation on 3D FLAIR using a deep-learning based tool (red mask); <bold>b</bold> new brain lesion segmentation at follow-up identified with the help of a deep-learning based tool and registration (green mask); <bold>c</bold> baseline spinal cord lesions segmentation on sagittal T2 using a deep-learning based tool (red mask); <bold>d</bold> manual segmentation of a new spinal cord lesion segmentation at follow-up (green mask)</p></caption><graphic xlink:href="415_2025_13068_Fig1_HTML" id="MO1"/></fig></p></sec></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par15">Baseline characteristics of the study population and the occurrence of new brain and spinal cord lesions during symptomatic and asymptomatic intervals were described using means with standard deviations for continuous variables and frequencies with percentages for categorical variables. For some non-normally distributed variables, medians with interquartile ranges (IQRs) were displayed.</p><p id="Par16">Univariate logistic regression was first conducted to assess potential factors associated with the occurrence of new brain or spinal cord lesions (sex (ref. Women), age, MS duration, therapeutic strategy (ref. HET), relapses (year before), EDSS, number of SC lesion(s), number of brain lesion(s), new SC lesion(s), new brain lesion(s)). Variables with a <italic>p</italic>-value &#x0003c;&#x02009;0.20 in the univariate analysis were then included in the final multivariable logistic regression. A <italic>p</italic>-value of less than 0.05 was considered statistically significant.</p><p id="Par17">The time to first relapse or disability progression for patients with new brain or spinal cord lesions between groups were studied using Kaplan&#x02013;Meier method with the corresponding log-rank test.</p><p id="Par18">Given that multiple scans were obtained per patient over time, a patient effect was applied to account for the correlation between repeated measurements within the same patient. The analyses were performed using R (version 4.2.3).</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Baseline and follow-up patients&#x02019; characteristics</title><p id="Par19">The baseline demographical, clinical and imaging characteristics of the population are detailed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. A total of 68 individuals with RRMS were included with a mean age of 31.5 years (SD =&#x02009;6.4) at first MRI acquisition. Overall, pwMS had a short disease duration (mean =&#x02009;8.2 months, SD =&#x02009;4 months), a low EDSS score (median =&#x02009;1 [IQR =&#x02009;0&#x02013;2]) and a wide range of brain and spinal cord lesion number (median =&#x02009;22, IQR =&#x02009;8&#x02013;37 and 3, IQR =&#x02009;2&#x02013;6, respectively).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">People with RRMS</th></tr></thead><tbody><tr><td align="left"/><td align="left"><italic>N</italic>&#x02009;= 68</td></tr><tr><td align="left">Gender&#x02014;<italic>F</italic> (%)</td><td align="left">44 (64.7)</td></tr><tr><td align="left">Age (years)&#x02014;mean (SD)</td><td align="left">31.5 (6.4)</td></tr><tr><td align="left">MS duration (months)&#x02014;mean (SD)</td><td align="left">8.2 (4,0)</td></tr><tr><td align="left">Annual relapse rate from MS onset to baseline&#x02014;mean (SD)</td><td align="left">0.5 (0.3)</td></tr><tr><td align="left">EDSS at inclusion&#x02014;<italic>N</italic> (%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;0</td><td align="left">29 (42.6)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">21 (30.9)</td></tr><tr><td align="left">&#x000a0;1.5</td><td align="left">5 (7.4)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">6 (8.8)</td></tr><tr><td align="left">&#x000a0;2.5</td><td align="left">4 (5.9)</td></tr><tr><td align="left">&#x000a0;3&#x02013;4</td><td align="left">3 (4.4)</td></tr><tr><td align="left">Volume of brain lesions (mm<sup>3</sup>)&#x02014;median [IQR]</td><td align="left">2164.4 [644.7, 5030.9]</td></tr><tr><td align="left">Number of brain lesions&#x02014;median [IQR]</td><td align="left">22.0 [8, 37]</td></tr><tr><td align="left">Volume of spinal cord lesions (mm<sup>3</sup>)&#x02014;median [IQR]</td><td align="left">455.75 [181.2, 951.2]</td></tr><tr><td align="left">Number of spinal cord lesions&#x02014;median [IQR]</td><td align="left">3.0 [2.0, 6.0]</td></tr></tbody></table><table-wrap-foot><p><italic>%</italic> percentage, <italic>SD</italic> standard deviation, <italic>N</italic> number, <italic>IQR</italic> interquartile range, <italic>EDSS</italic> Expanded Disability Status Scale</p></table-wrap-foot></table-wrap></p><p id="Par20">Over the 5-year follow-up, 221 intervals from the 68 patients were analysed. The mean number of intervals per patient was 3.25 (1.1) and the mean follow-up duration was 4.7 (0.99) years (with a mean duration of 1.4 years for each interval). The temporal distribution of the intervals across sites is detailed in Supplementary Table 1. Of these 221 intervals, 42 (19%) were classified as symptomatic (i.e. with the occurrence of at least 1 relapse during the interval), whilst 179 (81%) were asymptomatic. Regarding therapeutic strategies, 114 intervals were considered as a period of treatment by MET (52%), 16 by HET (7%), 55 as untreated (25%) and 30 as a period of switch between therapy strategies (14%). Nine out of 68 patients experienced a significant EDSS increase.</p></sec><sec id="Sec12"><title>New brain and spinal cord lesions during follow-up</title><p id="Par21">Overall, when both symptomatic and asymptomatic intervals were considered, 97 out of 221 intervals (44%) had no new brain or SC lesion, 82 (37%) had only new brain lesion, 8 (4%) had only new SC lesion and 34 (15%) had both new brain and SC lesion. Amongst the 34 intervals with both new brain and SC lesions, the majority (25 out of 34) involved at least three new brain lesions.</p><p id="Par22">When only asymptomatic intervals were considered (<italic>n</italic>&#x02009;= 179), 4 intervals (2%) had isolated new SC lesions and 15 (8%) had both new brain and SC lesions. Of the 15 intervals with both new brain and SC lesions, the majority had at least three new brain lesions (10 out of 15). The results were very different when only symptomatic intervals were considered (<italic>n</italic>&#x02009;= 42), with 4 intervals (10%) with isolated new spinal cord lesions and 19 (45%) with both new brain and spinal cord lesions. These results are summarised in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Brain and spinal cord MRI activity according to clinical activity. Percentage of MRIs with brain and/or spinal cord new lesions. Brain+ : interval with new brain lesion; Brain&#x02212;: interval without new brain lesion; SC+ : interval with new spinal cord lesion; SC&#x02212;: interval without new spinal cord lesion</p></caption><graphic xlink:href="415_2025_13068_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>New cervical vs. thoracic spinal cord lesions during follow-up</title><p id="Par23">The occurrence of new cervical cord lesions was higher than thoracic lesions during follow-up. Of the 42 intervals with SC MRI activity (out of 221), 28 had one or more new cervical spinal cord lesions with no thoracic lesions (67%), six had both new cervical and thoracic lesions (14%), and only eight had one or more new thoracic lesions without new cervical lesions (19%).</p></sec><sec id="Sec14"><title>Factors associated with the occurrence of new brain or new spinal cord lesions</title><p id="Par24">In the multivariable analyses, the occurrence of a new SC lesion was positively associated with period of treatment switch (compared to periods under HET), with the number of brain lesions on the initial MRI scan of the interval and with the occurrence of new brain lesion(s) during the same interval (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). No significant association was found with the number of SC lesions on the initial MRI scan of the interval.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Factors associated with the occurrence of a new spinal cord lesion</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">Univariate</th><th align="left" rowspan="2"><italic>p</italic></th><th align="left">Multivariable</th><th align="left" rowspan="2"><italic>p</italic></th></tr><tr><th align="left">OR [95%IC]</th><th align="left">OR [95%IC]</th></tr></thead><tbody><tr><td align="left">Sex (ref. women)</td><td align="left">0.992 [0.890; 1.106]</td><td align="left">0.889</td><td align="left"/><td align="left"/></tr><tr><td align="left">Age</td><td align="left">0.996 [0.988;1.004]</td><td align="left">0.318</td><td align="left"/><td align="left"/></tr><tr><td align="left">Disease duration</td><td align="left">0.977 [0.934; 1.022]</td><td align="left">0.303</td><td align="left"/><td align="left"/></tr><tr><td align="left">Treatment (ref. HET)</td><td align="left"/><td align="left"><bold>0.003</bold></td><td align="left"/><td align="left"><bold>0.006</bold></td></tr><tr><td align="left">&#x000a0;MET</td><td align="left">0.998 [0.814; 1.223]</td><td align="left"/><td align="left">1.145 [0.909; 1.443]</td><td align="left"/></tr><tr><td align="left">&#x000a0;SWITCH</td><td align="left">1.316 [1.039;1.668]</td><td align="left"/><td align="left">1.385 [1.061; 1.808]</td><td align="left"/></tr><tr><td align="left">&#x000a0;UNTREATED</td><td align="left">1.138 [0,916; 1.414]</td><td align="left"/><td align="left">1.221 [0,960; 1.553]</td><td align="left"/></tr><tr><td align="left">Relapse (year before)</td><td align="left">1.043 [0,979; 1.111]</td><td align="left"><bold>0.189</bold></td><td align="left">1.049 [0.983; 1.119]</td><td align="left">0.147</td></tr><tr><td align="left">EDSS</td><td align="left">0.988 [0,938; 1.041]</td><td align="left">0.655</td><td align="left"/><td align="left"/></tr><tr><td align="left">Nb of SC lesion(s)</td><td align="left">1.003 [0.990; 1.016]</td><td align="left">0.623</td><td align="left"/><td align="left"/></tr><tr><td align="left">Nb of brain lesion(s)</td><td align="left">1.003 [1.001; 1.005]</td><td align="left"><bold>0.0003</bold></td><td align="left">1.002 [1.000; 1.004]</td><td align="left"><bold>0.015</bold></td></tr><tr><td align="left">New brain lesion(s)</td><td align="left">1.246 [1.127; 1.378]</td><td align="left"><bold>&#x0003c; 10</bold><sup><bold>&#x02013;4</bold></sup></td><td align="left">1.170 [1.041; 1.314]</td><td align="left"><bold>0.009</bold></td></tr></tbody></table><table-wrap-foot><p><italic>OR</italic> odd ratio, <italic>HET</italic> high efficacy therapy, <italic>MET</italic> medium efficacy therapy, <italic>Nb </italic>number, <italic>SC</italic> spinal cord, <italic>EDSS</italic> Expanded Disability Status Scale</p><p><italic>p</italic>-values&#x0003c;0.20 in the univariate analysis are shown in bold</p><p><italic>p</italic>-values&#x0003c;0.05 in the multivariate analysis are shown in bold</p></table-wrap-foot></table-wrap></p><p id="Par25">In the multivariable analyses, the occurrence of a new brain lesion was positively associated with the periods of treatment switch compared to periods under HET, and with the occurrence of new spinal cord lesion(s) during the same interval (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Again, no significant association was found with the number of spinal cord lesions on the first MRI.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Factors associated with the occurrence of a new brain lesion</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">Univariate</th><th align="left" rowspan="2"><italic>p</italic></th><th align="left">Multivariable</th><th align="left" rowspan="2"><italic>p</italic></th></tr><tr><th align="left">OR [95%IC]</th><th align="left">OR [95%IC]</th></tr></thead><tbody><tr><td align="left"><bold>Sex (ref. women)</bold></td><td align="left">0.960 [0.835; 1.101]</td><td align="left">0.550</td><td align="left"/><td align="left"/></tr><tr><td align="left">Age</td><td align="left">0.986 [0.976; 0,996]</td><td align="left"><bold>0.005</bold></td><td align="left">0.990 [0.979; 1.002]</td><td align="left">0.101</td></tr><tr><td align="left">MS duration</td><td align="left">0.915 [0.865; 0.967]</td><td align="left"><bold>0.002</bold></td><td align="left">0.957 [0.860; 1.064]</td><td align="left">0.411</td></tr><tr><td align="left">Treatment (ref. HET)</td><td align="left"/><td align="left"><bold>0.002</bold></td><td align="left"/><td align="left"><bold>0.022</bold></td></tr><tr><td align="left">&#x000a0;MET</td><td align="left">1.154 [0.893; 1.492]</td><td align="left"/><td align="left">1.272 [0.943; 1.715]</td><td align="left"/></tr><tr><td align="left">&#x000a0;SWITCH</td><td align="left">1.628 [1.210; 2,192]</td><td align="left"/><td align="left">1.555 [1.103; 2.194]</td><td align="left"/></tr><tr><td align="left">&#x000a0;UNTREATED</td><td align="left">1.285 [0,979; 1.688]</td><td align="left"/><td align="left">1.299[0,949; 1.779]</td><td align="left"/></tr><tr><td align="left">Relapses (year before)</td><td align="left">1.140 [1.054; 1.234]</td><td align="left"><bold>0.001</bold></td><td align="left">1.083 [0.971; 1.206]</td><td align="left">0.150</td></tr><tr><td align="left">EDSS</td><td align="left">1.026 [0.959; 1.097]</td><td align="left">0.459</td><td align="left"/><td align="left"/></tr><tr><td align="left">Nb of SC lesion(s)</td><td align="left">1.011 [0.994; 1.029]</td><td align="left">0.194</td><td align="left">1.003 [0.985; 1.020]</td><td align="left">0.761</td></tr><tr><td align="left">Nb of brain lesion(s)</td><td align="left">1.003 [1.001; 1.006]</td><td align="left"><bold>0.011</bold></td><td align="left">1.002 [0.999; 1.004]</td><td align="left">0.203</td></tr><tr><td align="left">New SC lesion(s)</td><td align="left">1.429 [1.214; 1.682]</td><td align="left"><bold>&#x0003c; 10</bold><sup><bold>&#x02013;4</bold></sup></td><td align="left">1.288 [1.060; 1.566]</td><td align="left"><bold>0.011</bold></td></tr></tbody></table><table-wrap-foot><p>OR odd ratio, HET high efficacy therapy, MET medium efficacy therapy, Nb number, SC spinal cord, EDSS Expanded Disability Status Scale</p><p><italic>p</italic>-values&#x0003c;0.20 in the univariate analysis are shown in bold</p><p><italic>p</italic>-values&#x0003c;0.05 in the multivariate analysis are shown in bold</p></table-wrap-foot></table-wrap></p><sec id="Sec15"><title>Impact of new spinal cord lesions compared to new brain lesion only on the time to first relapse or disability progression</title><p id="Par26">The time to first relapse was not significantly shorter in patients with at least a new SC lesion compared to patients with at least a new brain lesion only (<italic>p</italic>&#x02009;= 0.57, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), whilst the time to first relapse was significantly decreased in patients with MRI activity (brain or SC) compared to those without MRI activity (<italic>p</italic>&#x02009;= 0.0039).<fig id="Fig3"><label>Fig. 3</label><caption><p>Time (months) to first relapse in patients with a new spinal cord lesion compared to patients with only new brain lesions</p></caption><graphic xlink:href="415_2025_13068_Fig3_HTML" id="MO3"/></fig></p><p id="Par27">The time to disability progression was not significantly shorter in patients with new SC lesions compared to patients with new brain lesions only (<italic>p</italic>&#x02009;= 0.64, supplementary figure). However, only 10 out of 68 patients experienced an EDSS significant increase during follow-up.</p></sec></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par28">In this retrospective study of a prospective cohort of early RRMS patients undergoing systematic brain and SC MRI follow-up according to a predetermined schedule for 5 consecutive years, we observed that SC MRI activity without concurrent clinical relapse and/or brain MRI activity was rare. The occurrence of new SC lesions was mainly associated with the number of brain lesions at baseline and the development of new brain lesions during follow-up, but not with the SC lesion load. Furthermore, the risk of relapse or disability progression following the detection of new SC lesions was not significantly increased compared to cases with only new brain lesions.</p><p id="Par29">Our study highlighted a low frequency (2%) of isolated new SC lesions in asymptomatic patients, consistent with a recent study limited to the cervical SC, which found a risk of 1.9% [<xref ref-type="bibr" rid="CR10">10</xref>] but contrasting with earlier studies [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>] that reported higher rates (around 10%). Several factors may explain our results. First, unlike previous studies, patients included in the present study were followed prospectively according to a predetermined MRI schedule. Retrospective designs often introduce selection bias, as SC MRIs in addition to brain MRIs are typically performed at the discretion of neurologists, often in patients with symptoms suggestive of SC involvement. Second, a deep learning tool to help new brain lesion detection was used, as it is increasingly the case in routine clinical practice. A semi-automated co-registration fusion software for comparing FLAIR sequence was also used in Lim et al. [<xref ref-type="bibr" rid="CR10">10</xref>]. These tools improve the detection of brain lesions, potentially reducing the proportion of patients classified as having isolated SC lesions by identifying concurrent brain lesions more accurately [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The increasingly widespread use of HET in recent years could also have an impact on the risk of new SC lesions in recent studies. However, the majority of our cohort was treated with MET (as in the study by Lim et al.). A more recent cohort predominantly treated with HET might demonstrate an even lower rate of SC activity. Interestingly, our results were obtained using a protocol that included several SC sequences (sagittal T2, sagittal PSIR, axial T2* and 3DT1) and a double reading of the images. Thus, under real-world clinical conditions, the detection of SC lesions might be even lower. Our findings reinforce the current recommendations advocating for monitoring treatment efficacy based on brain MRI alone, unless symptoms suggestive of SC are present [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par30">Moreover, in our study, the number of baseline SC lesions was not associated with the appearance of new SC lesions during follow-up, whilst the number of baseline brain lesions and the presence of new brain lesions were. This association between SC and brain MRI activity has been reported in previous studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and suggests that the overall inflammatory activity of a given patient plays a more significant role in the development of new SC lesions than the initial SC involvement itself. It is worth noting that current international guidelines recommend systematic SC MRI follow-up in patients with predominantly SC phenotypes [<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, further studies are needed to assess the risk of new SC versus brain lesions in patients with isolated SC lesions or a predominance of spinal cord lesions (i.e. with only a few brain lesions).</p><p id="Par31">Finally, in our study, the risk of new clinical relapses during follow up was associated with MRI activity during a previous interval (regardless of lesion location). However, no significant difference was observed between patients with new cerebral lesions only and those with new SC lesions. This result is in line with previous studies which also showed that new SC lesions, independently of new brain lesions, were not associated with shorter time to first relapse [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par32">Our study has several limitations that should be considered. First, our cohort is limited to 68 patients, although a total of 221 intervals were analysed. Second, our SC acquisition protocol was more detailed (four sequences) than what is routinely performed which may limit generalizability to clinical practice as this might have led to a higher detection rate of SC lesions. On the contrary, although the number of spinal cord sequences used in this study is substantial, we cannot exclude that the use of recent sequences such as MP2RAGE [<xref ref-type="bibr" rid="CR26">26</xref>] or the use of 7&#x000a0;T MRI [<xref ref-type="bibr" rid="CR27">27</xref>] would not have resulted in a higher detection rate of new spinal cord lesions. Spinal cord lesions are indeed difficult to detect, and similar studies, conducted with new, potentially more sensitive sequences, are yet to be carried out. Furthermore, in contrast to other studies [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], our research protocol did not include post-gadolinium injection imaging. However, previous studies report no clear added value of gadolinium injection on new spinal cord lesion detection [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In addition, the inclusion criteria of our study, which focussed on patients in the early stages of the disease with significant baseline brain or SC lesion loads, selected a subpopulation particularly at risk of MRI activity. However, these biases have likely led to an overestimation of SC activity compared to a more general MS population, and therefore, strengthens our conclusion regarding the low added value of routine SC MRI. Finally, our patient cohort remained relatively stable in terms of disability over the 5&#x000a0;years of follow-up. The prognostic value of the occurrence of new asymptomatic SC lesions versus the occurrence of new brain lesions could therefore not be accurately assessed, and would have required a larger cohort with longer follow-up.</p><p id="Par33">In conclusion, we found that the proportion of new isolated SC lesions in asymptomatic pwMS was low (2%) and that the occurrence of a new SC lesion was strongly associated with the occurrence of concurrent new brain lesions. These findings support the current guidelines recommending routine disease monitoring with brain MRI alone, even in patients with high SC lesion loads, unless specific clinical indications for SC imaging are present.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="415_2025_13068_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 2687 KB)</p></caption></media></supplementary-material></p></sec></body><back><ack><title>Acknowledgements</title><p>We are grateful for the tremendous efforts made by all EMISEP study teams across participating sites. Furthermore, we express our sincere gratitude to all the volunteers who are participating in the EMISEP study. We gratefully acknowledge all the administrative, medical and scientific staff members involved in data acquisition, data management, and quality control.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Centre Hospitalier Universitaire de Rennes. This research was supported by the French Hospital Programme of Clinical Research (PHRC).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The raw data supporting the findings of this study are available at <ext-link ext-link-type="uri" xlink:href="https://osf.io/rew7f/">https://osf.io/rew7f/</ext-link></p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par34">The authors report no competing interests in relation to the work described here.</p></notes><notes id="FPar2"><title>Ethical standard statement</title><p>The study was approved by the French Institutional Review Board OUEST V (13/18-898). Written informed consent was obtained from all participants.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lukas</surname><given-names>C</given-names></name><name><surname>Sombekke</surname><given-names>MH</given-names></name><name><surname>Bellenberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients</article-title><source>Radiology</source><year>2013</year><volume>269</volume><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">23737540</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lukas C, Sombekke MH, Bellenberg B et al (2013) Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology 269:542&#x02013;552<pub-id pub-id-type="pmid">23737540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Banwell</surname><given-names>BL</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><etal/></person-group><article-title>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria</article-title><source>Lancet Neurol</source><year>2018</year><volume>17</volume><fpage>162</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">29275977</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162&#x02013;173<pub-id pub-id-type="pmid">29275977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>WJ</given-names></name><name><surname>Altmann</surname><given-names>DR</given-names></name><name><surname>Prados</surname><given-names>F</given-names></name><etal/></person-group><article-title>Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis</article-title><source>Brain</source><year>2019</year><volume>142</volume><fpage>2276</fpage><lpage>2287</lpage><pub-id pub-id-type="pmid">31342055</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Brownlee WJ, Altmann DR, Prados F et al (2019) Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142:2276&#x02013;2287<pub-id pub-id-type="pmid">31342055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Arrambide</surname><given-names>G</given-names></name><name><surname>Rovira</surname><given-names>A</given-names></name><name><surname>Sastre-Garriga</surname><given-names>J</given-names></name><etal/></person-group><article-title>Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor</article-title><source>Mult Scler</source><year>2018</year><volume>24</volume><fpage>301</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">28301287</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Arrambide G, Rovira A, Sastre-Garriga J et al (2018) Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler 24:301&#x02013;312<pub-id pub-id-type="pmid">28301287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wattjes</surname><given-names>MP</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name><name><surname>Reich</surname><given-names>DS</given-names></name><etal/></person-group><article-title>2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis</article-title><source>Lancet Neurol</source><year>2021</year><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00095-8</pub-id><pub-id pub-id-type="pmid">34139157</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wattjes MP, Ciccarelli O, Reich DS et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 10.1016/S1474-4422(21)00095-8<pub-id pub-id-type="pmid">34139157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Ostini</surname><given-names>C</given-names></name><name><surname>Bovis</surname><given-names>F</given-names></name><name><surname>Disanto</surname><given-names>G</given-names></name><etal/></person-group><article-title>Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis</article-title><source>J Clin Med Res</source><year>2021</year><pub-id pub-id-type="doi">10.3390/jcm10030463</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ostini C, Bovis F, Disanto G et al (2021) Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis. J Clin Med Res. 10.3390/jcm10030463</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggieri</surname><given-names>S</given-names></name><name><surname>Prosperini</surname><given-names>L</given-names></name><name><surname>Petracca</surname><given-names>M</given-names></name><etal/></person-group><article-title>The added value of spinal cord lesions to disability accrual in multiple sclerosis</article-title><source>J Neurol</source><year>2023</year><volume>270</volume><fpage>4995</fpage><lpage>5003</lpage><pub-id pub-id-type="pmid">37386292</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ruggieri S, Prosperini L, Petracca M et al (2023) The added value of spinal cord lesions to disability accrual in multiple sclerosis. J Neurol 270:4995&#x02013;5003<pub-id pub-id-type="pmid">37386292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zecca</surname><given-names>C</given-names></name><name><surname>Disanto</surname><given-names>G</given-names></name><name><surname>Sormani</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis</article-title><source>Mult Scler</source><year>2016</year><volume>22</volume><fpage>782</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">26459149</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zecca C, Disanto G, Sormani MP et al (2016) Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler 22:782&#x02013;791<pub-id pub-id-type="pmid">26459149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Granella</surname><given-names>F</given-names></name><name><surname>Tsantes</surname><given-names>E</given-names></name><name><surname>Graziuso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey</article-title><source>J Neurol</source><year>2019</year><volume>266</volume><fpage>3031</fpage><lpage>3037</lpage><pub-id pub-id-type="pmid">31494713</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Granella F, Tsantes E, Graziuso S et al (2019) Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. J Neurol 266:3031&#x02013;3037<pub-id pub-id-type="pmid">31494713</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>TRU</given-names></name><name><surname>Kumaran</surname><given-names>SP</given-names></name><name><surname>Suthiphosuwan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis</article-title><source>Mult Scler</source><year>2024</year><volume>30</volume><fpage>505</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">38419027</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lim TRU, Kumaran SP, Suthiphosuwan S et al (2024) Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis. Mult Scler 30:505&#x02013;515<pub-id pub-id-type="pmid">38419027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Galler</surname><given-names>S</given-names></name><name><surname>Stellmann</surname><given-names>J-P</given-names></name><name><surname>Young</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Improved lesion detection by using axial T2-weighted MRI with full spinal cord coverage in multiple sclerosis</article-title><source>AJNR Am J Neuroradiol</source><year>2016</year><volume>37</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">26744444</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Galler S, Stellmann J-P, Young KL et al (2016) Improved lesion detection by using axial T2-weighted MRI with full spinal cord coverage in multiple sclerosis. AJNR Am J Neuroradiol 37:963&#x02013;969<pub-id pub-id-type="pmid">26744444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Fechner</surname><given-names>A</given-names></name><name><surname>Savatovsky</surname><given-names>J</given-names></name><name><surname>El Methni</surname><given-names>J</given-names></name><etal/></person-group><article-title>A 3T phase-sensitive inversion recovery MRI sequence improves detection of cervical spinal cord lesions and shows active lesions in patients with multiple sclerosis</article-title><source>AJNR Am J Neuroradiol</source><year>2019</year><volume>40</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">30679225</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Fechner A, Savatovsky J, El Methni J et al (2019) A 3T phase-sensitive inversion recovery MRI sequence improves detection of cervical spinal cord lesions and shows active lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol 40:370&#x02013;375<pub-id pub-id-type="pmid">30679225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Poonawalla</surname><given-names>AH</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Cervical spinal cord lesions in multiple sclerosis: T1-weighted inversion-recovery MR imaging with phase-sensitive reconstruction</article-title><source>Radiology</source><year>2008</year><volume>246</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">17991786</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Poonawalla AH, Hou P, Nelson FA et al (2008) Cervical spinal cord lesions in multiple sclerosis: T1-weighted inversion-recovery MR imaging with phase-sensitive reconstruction. Radiology 246:258&#x02013;264<pub-id pub-id-type="pmid">17991786</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mirafzal</surname><given-names>S</given-names></name><name><surname>Goujon</surname><given-names>A</given-names></name><name><surname>Deschamps</surname><given-names>R</given-names></name><etal/></person-group><article-title>3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis</article-title><source>J Neurol</source><year>2020</year><volume>267</volume><fpage>406</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">31655891</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mirafzal S, Goujon A, Deschamps R et al (2020) 3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis. J Neurol 267:406&#x02013;414<pub-id pub-id-type="pmid">31655891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Rovira</surname><given-names>A</given-names></name><name><surname>Corral</surname><given-names>JF</given-names></name><name><surname>Auger</surname><given-names>C</given-names></name><etal/></person-group><article-title>Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients</article-title><source>Mult Scler</source><year>2021</year><volume>28</volume><issue>8</issue><fpage>1209</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">34859704</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rovira A, Corral JF, Auger C et al (2021) Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. Mult Scler 28(8):1209&#x02013;1218<pub-id pub-id-type="pmid">34859704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Comb&#x000e8;s</surname><given-names>B</given-names></name><name><surname>Kerbrat</surname><given-names>A</given-names></name><name><surname>Pasquier</surname><given-names>G</given-names></name><etal/></person-group><article-title>A clinically-compatible workflow for computer-aided assessment of brain disease activity in multiple sclerosis patients</article-title><source>Front Med</source><year>2021</year><volume>8</volume><fpage>740248</fpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Comb&#x000e8;s B, Kerbrat A, Pasquier G et al (2021) A clinically-compatible workflow for computer-aided assessment of brain disease activity in multiple sclerosis patients. Front Med 8:740248</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Comb&#x000e8;s</surname><given-names>B</given-names></name><name><surname>Kerbrat</surname><given-names>A</given-names></name><name><surname>Ferr&#x000e9;</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Focal and diffuse cervical spinal cord damage in patients with early relapsing&#x02013;remitting MS: a multicentre magnetisation transfer ratio study</article-title><source>Mult Scler</source><year>2019</year><volume>25</volume><fpage>1113</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">29909771</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Comb&#x000e8;s B, Kerbrat A, Ferr&#x000e9; JC et al (2019) Focal and diffuse cervical spinal cord damage in patients with early relapsing&#x02013;remitting MS: a multicentre magnetisation transfer ratio study. Mult Scler 25:1113&#x02013;1123<pub-id pub-id-type="pmid">29909771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gaubert</surname><given-names>M</given-names></name><name><surname>Comb&#x000e8;s</surname><given-names>B</given-names></name><name><surname>Bannier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Microstructural damage and repair in the spinal cord of patients with early multiple sclerosis and association with disability at 5 years</article-title><source>Neurol Neuroimmunol Neuroinflamm</source><year>2025</year><volume>12</volume><fpage>e200333</fpage><pub-id pub-id-type="pmid">39571137</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gaubert M, Comb&#x000e8;s B, Bannier E et al (2025) Microstructural damage and repair in the spinal cord of patients with early multiple sclerosis and association with disability at 5 years. Neurol Neuroimmunol Neuroinflamm 12:e200333<pub-id pub-id-type="pmid">39571137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Polman</surname><given-names>CH</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name><name><surname>Banwell</surname><given-names>B</given-names></name><etal/></person-group><article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>292</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">21387374</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292&#x02013;302<pub-id pub-id-type="pmid">21387374</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Isensee</surname><given-names>F</given-names></name><name><surname>Jaeger</surname><given-names>PF</given-names></name><name><surname>Kohl</surname><given-names>SAA</given-names></name><etal/></person-group><article-title>nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation</article-title><source>Nat Methods</source><year>2021</year><volume>18</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">33288961</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Isensee F, Jaeger PF, Kohl SAA et al (2021) nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 18:203&#x02013;211<pub-id pub-id-type="pmid">33288961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Yushkevich</surname><given-names>PA</given-names></name><name><surname>Piven</surname><given-names>J</given-names></name><name><surname>Hazlett</surname><given-names>HC</given-names></name><etal/></person-group><article-title>User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><fpage>1116</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">16545965</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yushkevich PA, Piven J, Hazlett HC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31:1116&#x02013;1128<pub-id pub-id-type="pmid">16545965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Behrens</surname><given-names>TEJ</given-names></name><etal/></person-group><source>FSL Neuroimage</source><year>2012</year><volume>62</volume><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">21979382</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Jenkinson M, Beckmann CF, Behrens TEJ et al (2012) FSL Neuroimage 62:782&#x02013;790<pub-id pub-id-type="pmid">21979382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Dahan</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Malpas</surname><given-names>CB</given-names></name><etal/></person-group><article-title>PACS integration of semiautomated imaging software improves day-to-day MS disease activity detection</article-title><source>AJNR Am J Neuroradiol</source><year>2019</year><volume>40</volume><fpage>1624</fpage><lpage>1629</lpage><pub-id pub-id-type="pmid">31515214</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dahan A, Pereira R, Malpas CB et al (2019) PACS integration of semiautomated imaging software improves day-to-day MS disease activity detection. AJNR Am J Neuroradiol 40:1624&#x02013;1629<pub-id pub-id-type="pmid">31515214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Galletto Pregliasco</surname><given-names>A</given-names></name><name><surname>Collin</surname><given-names>A</given-names></name><name><surname>Gu&#x000e9;guen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improved detection of new MS lesions during follow-up using an automated MR coregistration-fusion method</article-title><source>AJNR Am J Neuroradiol</source><year>2018</year><volume>39</volume><fpage>1226</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">29880479</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Galletto Pregliasco A, Collin A, Gu&#x000e9;guen A et al (2018) Improved detection of new MS lesions during follow-up using an automated MR coregistration-fusion method. AJNR Am J Neuroradiol 39:1226&#x02013;1232<pub-id pub-id-type="pmid">29880479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>JW</given-names></name><name><surname>Kidd</surname><given-names>D</given-names></name><name><surname>Moseley</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis</article-title><source>Neurology</source><year>1996</year><volume>46</volume><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">8614497</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Thorpe JW, Kidd D, Moseley IF et al (1996) Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 46:373&#x02013;378<pub-id pub-id-type="pmid">8614497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Demorti&#x000e8;re</surname><given-names>S</given-names></name><name><surname>Lehmann</surname><given-names>P</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improved cervical cord lesion detection with 3D-MP2RAGE sequence in patients with multiple sclerosis</article-title><source>AJNR Am J Neuroradiol</source><year>2020</year><volume>41</volume><fpage>1131</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">32439640</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Demorti&#x000e8;re S, Lehmann P, Pelletier J et al (2020) Improved cervical cord lesion detection with 3D-MP2RAGE sequence in patients with multiple sclerosis. AJNR Am J Neuroradiol 41:1131&#x02013;1134<pub-id pub-id-type="pmid">32439640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Testud</surname><given-names>B</given-names></name><name><surname>Fabiani</surname><given-names>N</given-names></name><name><surname>Demorti&#x000e8;re</surname><given-names>S</given-names></name><etal/></person-group><article-title>Contribution of the MP2RAGE 7T sequence in MS lesions of the cervical spinal cord</article-title><source>AJNR Am J Neuroradiol</source><year>2023</year><volume>44</volume><fpage>1101</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">37562829</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Testud B, Fabiani N, Demorti&#x000e8;re S et al (2023) Contribution of the MP2RAGE 7T sequence in MS lesions of the cervical spinal cord. AJNR Am J Neuroradiol 44:1101&#x02013;1107<pub-id pub-id-type="pmid">37562829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Sabatino</surname><given-names>E</given-names></name><name><surname>Gaetani</surname><given-names>L</given-names></name><name><surname>Sperandei</surname><given-names>S</given-names></name><etal/></person-group><article-title>The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI</article-title><source>J Neurol</source><year>2022</year><volume>269</volume><fpage>3129</fpage><lpage>3135</lpage><pub-id pub-id-type="pmid">34820734</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Di Sabatino E, Gaetani L, Sperandei S et al (2022) The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. J Neurol 269:3129&#x02013;3135<pub-id pub-id-type="pmid">34820734</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>